ERBB2 and ependymoma: A phase I clinical trial that will assess the efficacy of HER2-specific CAR-T cell locoregional immunotherapy in patients with HER2-positive recurrent or refractory pediatric CNS tumors, including ependymomas, is also currently in the recruitment phase (NCT03500991).